Country: Sweden
Language: Swedish
Source: Läkemedelsverket (Medical Products Agency)
deferasirox
Teva Sweden AB
V03AC03
deferasirox
500 mg
Dispergerbar tablett
laktosmonohydrat Hjälpämne; deferasirox 500 mg Aktiv substans; natriumlaurilsulfat Hjälpämne
Receptbelagt
Förpacknings: Blister, 28 tabletter; Blister, 30 tabletter; Blister, 84 tabletter; Blister, 98 tabletter; Blister, 28 x 1 tabletter (endos); Blister, 30 x 1 tabletter (endos); Blister, 84 x 1 tabletter (endos); Blister, 98 x 1 tabletter (endos); Blister, 294 (3 x 98) tabletter
Godkänd
2017-09-29
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DEFERASIROX TEVA 125 MG DISPERSIBLE TABLETS DEFERASIROX TEVA 250 MG DISPERSIBLE TABLETS DEFERASIROX TEVA 500 MG DISPERSIBLE TABLETS deferasirox READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed only for you or your child. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. Whatis and what it is used for 2. What you need to know before you take Read the complete document3. How to take 4. Possible side effects 5. How to store 6. Contents of the pack and other information 1. WHAT IS AND WHAT IT IS USED FOR WHAT IS contains an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload). It traps and removes excess iron which is then excreted mainly in the stools. WHAT IS USED FOR Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can cause a build-up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions. In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medi
1 SUMMARY OF PRODUCT CHARACTERISTICS Deferasirox, SE/H/1885/001-003, 01.10.2018 reduction of shelf life from 36 months to 24 months 2 1. NAME OF THE MEDICINAL PRODUCT Deferasirox Teva 125 mg dispersible tablets Deferasirox Teva 250 mg dispersible tablets Deferasirox Teva 500 mg dispersible tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dispersible tablet contains 125 mg of deferasirox. Each dispersible tablet contains 250 mg of deferasirox. Each dispersible tablet contains 500 mg of deferasirox. Excipient with known effect Each dispersible tablet contains 85 mg lactose monohydrate. Each dispersible tablet contains 171mg lactose monohydrate. Each dispersible tablet contains 341 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Dispersible tablet 125 mg dispersible tablets White to off-white, round, flat tablets with bevelled edges and debossing 77 on one side and 438 on the other side. Diameter of each tablet is approx. 12 mm. 250 mg dispersible tablets White to off-white, round, flat tablets with bevelled edges and debossing 77 on one side and 439 on the other side. Diameter of each tablet is approx. 15 mm. 500 mg dispersible tablets White to off-white, round, flat tablets with bevelled edges and debossing 77 on one side and 440 on the other side. Diameter of each tablet is approx. 20 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONSis indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. Read the complete documentis also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: - in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years, - in adult and paediatric patients with beta th